Bryxta 400mg

Bryxta 400 is a branded version of bevacizumab, a humanized monoclonal antibody used to treat various types of cancer. It is a sterile, clear to slightly yellowish liquid solution in a single-dose vial.

Composition:

Each 400 mg injection of Bryxta 400 Bevacizumab 400 mg contains bevacizumab, a humanized monoclonal antibody that targets the vascular endothelial growth factor (VEGF) pathway.

• Bevacizumab (humanized monoclonal antibody)
• L-histidine
• Polysorbate 20
• Sodium chloride
• Water for injection

Mechanism of Action:

Bevacizumab binds to vascular endothelial growth factor (VEGF) A and inhibits the interaction of VEGF with its receptors, thereby reducing angiogenesis, tumor growth, and metastasis.

Use:

Bryxta 400 is indicated for the treatment of:

1. Metastatic colorectal cancer (mCRC) in combination with fluorouracil-based chemotherapy.
2. Non-small cell lung cancer (NSCLC) in combination with carboplatin and paclitaxel.
3. Renal cell carcinoma (RCC) in patients who have received prior anti-angiogenic therapy.
4. Cervical cancer in combination with chemotherapy.

Dosage:

• The recommended dosage of Bryxta 400 is:
  • 5 mg/kg every 2 weeks for mCRC.
  • 7.5 mg/kg every 3 weeks for NSCLC.
  • 10 mg/kg every 2 weeks for RCC.
  • 15 mg/kg every 3 weeks for cervical cancer.

Side Effects:

Common side effects associated with Bryxta 400 include:

• Hypertension
• Proteinuria
• Epistaxis
• Nausea
• Fatigue
• Headache
• Infection

Serious side effects can include:

• Arterial thromboembolic events (ATEs)
• Gastrointestinal perforation
• Fistulae formation
• Hemorrhage

Recommendation:

• Patients should be monitored regularly for hypertension, proteinuria, and other side effects.
• Patients with a history of hypertension, hypertension-related disorders, or proteinuria should be closely monitored.
• Patients should be advised to report any signs or symptoms of ATEs, gastrointestinal perforation, fistulae formation, or hemorrhage promptly.

Important Note:

• Bryxta 400 is contraindicated in patients with a history of hypersensitivity to bevacizumab or any of its components.
• Patients with a history of stroke or TIA within the past 6 months should not receive Bryxta 400.
• Patients with a history of arterial aneurysms should not receive Bryxta 400.
• Patients with a history of gastrointestinal perforation or fistulae should not receive Bryxta 400.